Weekly Analysts’ Ratings Updates for Cryolife (CRY)

Cryolife (NYSE: CRY) has recently received a number of price target changes and ratings updates:

  • 3/13/2018 – Cryolife was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife’s BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. “
  • 3/9/2018 – Cryolife had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $28.00 price target on the stock, up previously from $25.00.
  • 3/8/2018 – Cryolife had its “buy” rating reaffirmed by analysts at Northland Securities. They now have a $23.50 price target on the stock. They wrote, “SER-109 stumbles do not impact the long game, in our view. To us, the attractiveness of MCRB’s C. difficile infection (CDI) programs is more about establishing proof of concept (POC) that the microbiome can be manipulated for therapeutic purposes than their revenue potential. If the IBD and/or cancer immunotherapy programs are successful, we believe far larger commercial opportunities could emerge.””
  • 3/7/2018 – Cryolife was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 1/16/2018 – Cryolife was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife’s BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. “

Cryolife Inc (NYSE:CRY) opened at $20.85 on Friday. Cryolife Inc has a fifty-two week low of $14.02 and a fifty-two week high of $24.00. The company has a current ratio of 4.18, a quick ratio of 4.90 and a debt-to-equity ratio of 0.81. The stock has a market cap of $692.57, a PE ratio of 208.52 and a beta of 0.75.

How to Become a New Pot Stock Millionaire

Cryolife (NYSE:CRY) last posted its quarterly earnings data on Wednesday, March 7th. The medical equipment provider reported $0.11 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.11. Cryolife had a net margin of 1.95% and a return on equity of 5.93%. The firm had revenue of $52.80 million for the quarter, compared to the consensus estimate of $48.40 million. During the same quarter in the prior year, the company posted $0.09 earnings per share. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. sell-side analysts forecast that Cryolife Inc will post 0.09 EPS for the current year.

In other news, Director C Elkins Ronald sold 2,000 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $22.00, for a total transaction of $44,000.00. Following the transaction, the director now owns 97,849 shares in the company, valued at $2,152,678. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.00% of the company’s stock.

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply